SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of ~~earliest~~ earliest event reported): ~~September~~June 131, ~~2003~~2004

QUINTILES TRANSNATIONAL CORP. ~~(Exact name of registrant as specified in its charter)~~

~~North Carolina~~ (~~State~~Exact orname ~~other jurisdiction~~ of ~~incorporation)~~registrant ~~000-23520~~as ~~(Commission~~specified ~~File~~in ~~No.)~~its ~~56-1714315 (I.R.S. Employer Identification Number~~charter)


North Carolina (State or other jurisdiction of incorporation)		000-23520 (Commission File No.)		56-1714315 I.R.S. Employer Identification Number

4709 Creekstone Drive, Riverbirch Building, Suite 200, Durham, North Carolina 27703-8411
(Address of principal executive offices)

(919) 998-2000
(Registrant’s telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Item 5 9. ~~Other Events and~~ Regulation FD Disclosure*.

OnIn ~~September~~May 132004, ~~2003,~~the ~~Quintiles~~Company’s ~~Transnational~~Board ~~Corp.~~of ~~(the~~Directors ~~“Company”)~~authorized management to ~~issued~~proceed with a ~~press~~plan ~~release~~of ~~announcing~~disposition ~~that~~for itthe ~~has~~assets ~~entered~~related ~~into~~to athe ~~purchase agreement~~Bioglan ~~dated~~Pharmaceuticals ~~September 12,~~Company ~~2003~~(“Bioglan”) ~~pursuant~~in tothe ~~which~~form ~~the Company~~of ~~intends~~a tosale ~~issue~~of ~~and~~assets. Currently, ~~sell~~the ~~$450 million~~Company ~~principal~~anticipates ~~amount~~the ofdisposition ~~senior~~will ~~subordinated notes~~be ~~due~~completed ~~2013~~during 2004. inThe aassets ~~transaction~~to ~~exempt~~be ~~from~~disposed ~~the~~of ~~registration~~are ~~requirements~~part of the ~~Securities~~PharmaBio ~~Act~~Development group’s ofstrategic ~~1933,~~investment asportfolio ~~amended,~~which inis ~~connection~~routinely analyzed to evaluate ~~with~~the ~~its~~return ~~merger~~potential ~~with~~of ~~Pharma~~the ~~Services~~assets ~~Acquisition~~within ~~Corp~~the portfolio., aThe ~~wholly~~Bioglan ~~owned~~assets ~~subsidiary~~include ofa ~~Pharma~~number ~~Services~~of ~~Intermediate~~dermatology ~~Holding~~products, ~~Inc~~including SolarazeTM and ADOXATM. The ~~press~~major ~~release~~classes isof ~~attached~~assets ~~hereto~~related to the assets to be disposed of included in the Company’s balance sheets as ~~Exhibit~~of March ~~99.01~~31, ~~and~~2004, isDecember 31, ~~incorporated~~2003 and ~~herein~~December 31, by2002 ~~reference.~~are as follows (in thousands):

Item 7. Financial Statements and Exhibits.


	As of		As of		As of
	March 31, 2004		December 31, 2003		December 31, 2002
Current assets	$	9,727	$	9,012	$	7,142
Property and equipment, net		488		536		340
Intangible assets		74,950		78,996		60,437
Other assets		5		5		—

Current liabilities		4,168		5,879		5,988
Long-term liabilities	$	37	$	41	$	—

~~(c) Exhibits~~ * The information in this Current Report on Form 8-K shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Furthermore, the information in this Current Report on Form 8-K shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended.

Exhibit Number		Description of Exhibit
99.01		Press Release of the Company, dated September 13, 2003

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	QUINTILES TRANSNATIONAL CORP.
	By:	/s/ John S. Russell
Dated: September 15, 2003		John S. Russell
		Executive Vice President


	QUINTILES TRANSNATIONAL CORP.
	By:	/s/ John S. Russell
		John S. Russell
		Executive Vice President and General Counsel Chief Administrative Officer

~~EXHIBIT~~Dated: ~~INDEX~~June 1, 2004

Exhibit Number		Description of Exhibit
99.01		Press Release of the Company, dated September 13, 2003

Filing Compare · QUINTILES TRANSNATIONAL CORP